The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Efficacy and safety of tigecycline: a systematic review and meta-analysis
Open accessAbstract
BACKGROUND: Tigecycline is a novel glycylcycline that exhibits broad-spectrum antibacterial activity. Recently, the US FDA issued a warning concerning increased mortality with tigecycline in randomized controlled trials (RCTs). METHODS: We conducted a systematic review and meta-analysis of RCTs that compared tigecycline with any other antibiotic regimen for the treatment of any infection. A comprehensive search, without publication status or other restrictions, was conducted. The primary outcome was overall 30 day mortality. The secondary outcome included clinical and microbiological failure, superinfections and adverse events (AEs). The trials' risks of bias and their effects on results were assessed. Two reviewers independently extracted the data. Individual trials' relative risks (RRs) were pooled using a fixed effect meta-analysis. RESULTS: Fifteen trials (7654 patients) were included. Overall mortality was higher with tigecycline compared with other regimens [RR 1.29, 95% confidence interval (CI) 1.02-1.64, without heterogeneity]. The type of infection assessed and the trials' reported risks of bias did not affect this result. Clinical failure was significantly higher with tigecycline (RR 1.16, 95% CI 1.06-1.27) and non-statistically significant higher rates of microbiological failure were demonstrated (RR 1.13, 95% CI 0.99-1.30). Development of septic shock was significantly more frequent with tigecycline (RR 7.01, 95% CI 1.27-38.66). Superinfections were significantly more common with tigecycline and so were AEs, including all AEs and AEs requiring discontinuation. CONCLUSIONS: In the light of the increased mortality, probably explained by decreased clinical and microbiological efficacy, clinicians should avoid tigecycline monotherapy in the treatment of severe infections and reserve it as a last-resort drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Paul, M., Shani, V., Muchtar, E., Kariv, G., Robenshtok, E., & Leibovici, L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00627-10 · Cited by 724
Self-citationEllis‐Grosse, E. J., Babinchak, T., Dartois, N., Rose, G., Loh, E., & Groups, T. 3. A. 3. C. S. (2005) · Clinical Infectious Diseases · doi:10.1086/431675 · Cited by 414
Babinchak, T., Ellis‐Grosse, E., Dartois, N., Rose, G. M., Loh, E., & Groups, T. 3. A. 3. S. (2005) · Clinical Infectious Diseases · doi:10.1086/431676 · Cited by 381
Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov
Bourgeois, F. T., Murthy, S., & Mandl, K. D. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00006 · Cited by 332
Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose
Rodvold, K. A., Gotfried, M. H., Cwik, M., Korth-Bradley, J. M., Dukart, G., & Ellis-Grosse, E. J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl403 · Cited by 304
Pankey, G. A. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki248 · Cited by 301
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
Freire, A. T., Melnyk, V., Kim, M. J., Datsenko, O., Dzyublik, O., Glumcher, F., Chuang, Y.-C., Maroko, R. T., Dukart, G., Cooper, C. A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.05.012 · Cited by 284
Tigecycline: A New Glycylcycline for Treatment of Serious Infections
Noskin, G. A. (2005) · Clinical Infectious Diseases · doi:10.1086/431672 · Cited by 226
Cited by
Tzouvelekis, L. S., Markogiannakis, A., Psichogiou, M., Tassios, P. T., & Daikos, G. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05035-11 · Cited by 1,191
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac268 · Cited by 526
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1013 · Cited by 519
“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
Current Epidemiology and Growing Resistance of Gram-Negative Pathogens
Livermore, D. M. (2012) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2012.27.2.128 · Cited by 417
Management of bacterial infections in cirrhosis
Fernández, J., & Gustot, T. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60002-6 · Cited by 368
Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future
Rodvold, K. A., & McConeghy, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit614 · Cited by 358
Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside
Lin, M.-F. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i12.787 · Cited by 357
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes
van Duin, D., Kaye, K. S., Neuner, E. A., & Bonomo, R. A. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.11.009 · Cited by 352
Falagas, M. E., Lourida, P., Poulikakos, P., Rafailidis, P. I., & Tansarli, G. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01222-13 · Cited by 351
Yaghoubi, S., Zekiy, A. O., Krutova, M., Gholami, M., Kouhsari, E., Sholeh, M., Ghafouri, Z., & Maleki, F. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-04121-1 · Cited by 332
Tängdén, T., & Giske, C. G. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12342 · Cited by 322
Cerceo, E., Deitelzweig, S. B., Sherman, B. M., & Amin, A. N. (2016) · Microbial Drug Resistance · doi:10.1089/mdr.2015.0220 · Cited by 313
Excess Deaths Associated With Tigecycline After Approval Based on Noninferiority Trials
Prasad, P., Sun, J., Danner, R. L., & Natanson, C. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis270 · Cited by 298
Colistin: new lessons on an old antibiotic
Yahav, D., Farbman, L., Leibovici, L., & Paul, M. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03734.x · Cited by 259
Self-citation
Metadata
- Authors
- Yahav, D., Lador, A., Paul, M., & Leibovici, L.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-06-18
- Volume
- 66
- Issue
- 9
- Pages
- 1963-1971
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2146287754
- Cited by
- 266
- References
- 39
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.